Apogee Therapeutics, Inc.
US ˙ NasdaqGM ˙ US03770N1019

SecurityAPGE / Apogee Therapeutics, Inc.
InstitutionAlliancebernstein L.p.
Latest Disclosed Ownership990,297 shares
Latest Disclosed Value $ 74,747,618
Alliancebernstein L.p. reports 9.45% decrease in ownership of APGE / Apogee Therapeutics, Inc.

On May 15, 2026 - Alliancebernstein L.p. filed a 13F-HR form disclosing ownership of 990,297 shares of Apogee Therapeutics, Inc. (US:APGE) valued at $83,353,298 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 1,093,657 shares of Apogee Therapeutics, Inc.. This represents a change in shares of -9.45% during the quarter. The current value of the position is $83,373,104 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F APOGEE THERAPEUTICS COM 03770N101 990,297 -103,360 -9.45 74,748 -9.45 0.0242
2026-02-17 2025-12-31 13F APOGEE THERAPEUTICS COM 03770N101 1,093,657 -325,475 -22.93 82,549 46.41 0.0261
2025-11-14 2025-09-30 13F APOGEE THERAPEUTICS COM 03770N101 1,419,132 30,983 2.23 56,382 -6.48 0.0178
2025-08-14 2025-06-30 13F APOGEE THERAPEUTICS COM 03770N101 1,388,149 107,199 8.37 60,287 25.98 0.0197
2025-05-15 2025-03-31 13F APOGEE THERAPEUTICS COM 03770N101 1,280,950 -74,235 -5.48 47,856 -22.04 0.0173
2025-02-12 2024-12-31 13F APOGEE THERAPEUTICS COM 03770N101 1,355,185 160,822 13.47 61,390 -12.50 0.0208
2024-11-14 2024-09-30 13F APOGEE THERAPEUTICS COM 03770N101 1,194,363 62,093 5.48 70,157 57.46 0.0236
2024-08-14 2024-06-30 13F APOGEE THERAPEUTICS COM 03770N101 1,132,270 387,152 51.96 44,555 -10.02 0.0155
2024-05-14 2024-03-31 13F APOGEE THERAPEUTICS COM 03770N101 745,118 734,478 6,902.99 49,513 16,571.04 0.0175
2024-02-14 2023-12-31 13F APOGEE THERAPEUTICS COM 03770N101 10,640 10,640 297 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.